Aruni Ghose, Co-Founder and Chief Medical Officer at OncoFlow and Clinical Research Fellow (Remote) at BALCO Medical Centre, shared a post on LinkedIn:
“Hot off the ARON2EV metastatic Urothelial Cancer Press!! High Impact European Urology European Association of Urology Group of Journals!
ARON-2EV is an international, multicentre, retrospective study examining the real world use of Enfortumab Vedotin (EV) in patients with mUC. The World’s Largest Dataset of its kind included 401 patients treated with EV following PBC (Platinum Based Chemotherapy)/PEM (Pembrolizumab). Median OS was 12.3 mo (95% confidence interval [CI] 9.9–14.3), median ToT was 10.4 mo (95% CI 9.0–12.2), and the ORR was 45%. Subgroup Analysis of progressive disease (PD) on prior PEM yielded 35% ORR. Implicates association between prior PEM outcomes and subsequent EV efficacy.
Priviledged to be in this Global GenitoUrinary God like Study Group.”
Title: Efficacy of Enfortumab Vedotin After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the ARON-2EV Cohort
Authors: Ondrej Fiala, Francesco Grillone, Kazutoshi Fujita, Enrique Grande, Patrizia Giannatempo, Tarek Taha, Zin W. Myint, Thomas Büttner, Alfonso Gómez de Liaño, Ravindran Kanesvaran, Gaetano Facchini, Akihiro Yano, Luigi Formisano, Alexandr Poprach, Vincenza Conteduca, Alina Pirshtuk, Hana Studentova, Jindrich Kopecky, Enrico Sammarco, Augusto Mota, Lorena Incorvaia, Cecilia Nasso, Michele Maffezzoli, Aruni Ghose, Andrey Soares, Sebastiano Buti, Fernando Sabino Marques Monteiro, Francesco Massari, Shilpa Gupta, Joaquim Bellmunt, Giuseppe Luigi Banna, Matteo Santoni
More posts featuring Aruni Ghose on OncoDaily.
